POLYOX™ Polyethylene Oxide Essentials: An Expert Guide to Polymer Properties and Drug Formulation

Specialty matrix drug delivery systems, like osmotic pump tablets, play an important role in patient-centric drug design. In this upcoming webinar, experts will delve into how one unique excipient, POLYOX™ polyethylene (PE) oxide, provides critical material properties that result in robust drug product performance.

Register Free: https://www.pharmtech.com/pt_w/oxide-essentials

Event Overview:

Advanced Drug Delivery: Harnessing the Unique Properties of POLYOX™ Polyethylene Oxide in Oral Solid Dosages

Specialty matrix systems, like osmotic pump tablets, offer an array of advantages in drug delivery, such as zero-order release profiles, no food effects, and targetable site of delivery. These benefits contribute to improved efficacy of the drug product in patient outcomes. One polymer stands out as being uniquely designed for use in osmotic pump tablets: POLYOX™ polyethylene oxide.

In this presentation, we explore the material properties of POLYOX™ that make the polymer well suited for specialty matrices. We will also cover the naturally degradative nature of polyethylene oxide, discussing how it impacts drug product performance and ways to overcome this challenge.

Key Learning Objectives:

• Understand key material attributes of POLYOX™ polyethylene oxide and how POLYOX™ is used in specialty matrix formulations
• Identify properties that impact polyethylene oxide degradation both in powder and in formulations
• Explore ways to overcome degradation challenges through storage conditions and packaging

Who Should Attend:

• Formulation and process who?
• Development scientists
• Drug product regulatory and quality
• Process engineers
• Supply chain
• Technical transfer and scale up scientists

Speaker:

Elizabeth Tocce, Ph.D.
Lead Applications Scientist
IFF
Elizabeth Tocce is a lead applications scientist for IFF Pharma Solutions, where she heads technical marketing projects promoting the expertise of the Pharma Solutions business unit.

Elizabeth joined the IFF Pharma Solutions team in 2018 as a pharma application development scientist. In this role, she provided technical support to pharmaceutical customers and project leadership on growth and innovation projects using IFF’s pharmaceutical excipients. Prior to her roles with IFF, Elizabeth was a research and development scientist for the Dow Chemical Company’s Pharma & Food Solutions excipient business where she led R&D projects in areas of specialty oral solid dosages and quality improvement.

Elizabeth received her Ph.D. in chemical and biological engineering from the University of Wisconsin in Madison.

Register Free: https://www.pharmtech.com/pt_w/oxide-essentials